Although various treatment modalities, such as cryotherapy, laser photocoagulation, and the use of anti-VEGF agents, have been well-established, novel therapeutics are required to curb the increasing prevalence of ROP. This evidence concerns the gene VEGFA and retinopathy of prematurity.